Finance

Lists
AGIO:NASDAQ
Agios Pharmaceuticals Inc
$32.82
0.00%
(0.00) 1D
Nov 11, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for AGIO...
Mkt. cap
1.96B
Avg. vol.
1.29M
Volume
33.00
52-wk high
$46.00
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
Mkt. cap
1.96B
Avg. vol.
1.29M
Volume
33.00
52-wk high
$46.00
52-wk low
$22.24
EPS
-$6.32
Beta
0.66
Shares outstanding
59.81M
No. of employees
540
News stories
From web sources and news partners
Profile
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013. Wikipedia
About Agios Pharmaceuticals Inc
CEO-
Employees540
Founded2008
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websiteagios.com
Analyst ratings
Based on 6 analysts giving stock ratings to AGIO in the past 3 months
Buy
Buy
4
Hold
2
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for AGIO in the last 3 months.
Highest
Current $32.82
$62.00 (+88.91%)
Average
$45.80 (+39.55%)
Lowest
$32.00 (-2.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Luca Issi
RBC Capital
Hold
Maintained
$32.00
-2.5%
11/05/2026
Alec Stranahan
Bank of America Securities
Buy
Reiterated
$48.00
+46.3%
11/06/2026
Douglas Tsao
H.C. Wainwright
Buy
Maintained
$62.00
+88.9%
11/06/2026
Gregory Renza
Truist Financial
Buy
Maintained
$35.00
+6.6%
11/06/2026
Tessa Romero
J.P. Morgan
Hold
Maintained
-
-
10/31/2026
Samantha Semenkow
Citi
Buy
Maintained
$52.00
+58.4%
10/28/2026
Marc Frahm
TD Cowen
Buy
Maintained
-
-
08/03/2026
Emily Bodnar
H.C. Wainwright
Buy
Maintained
$55.00
+67.6%
07/30/2026
Salveen Richter
Goldman Sachs
Hold
Maintained
$32.00
-2.5%
07/21/2026
Andrew Berens
Leerink Partners
Buy
Maintained
-
-
07/07/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
-$1.09 / -$1.23
+11.38%beat
Revenue / Est. (USD)
55.38M / 51.60M
+7.33%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
19.97M
20.75M
44.74M
55.38M
Cost of goods sold
89.94M
82.47M
103.75M
76.01M
Cost of revenue
89.94M
82.47M
103.75M
76.01M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
51.61M
48.30M
51.55M
56.53M
Operating expense
51.61M
48.30M
51.55M
56.53M
Total operating expenses
141.54M
130.77M
155.30M
132.54M
Operating income
-121.58M
-110.02M
-110.55M
-77.16M
Other non operating income
113.00K
119.00K
119.00K
3.24M
EBT including unusual items
-109.06M
-99.11M
-100.70M
-65.04M
EBT excluding unusual items
-109.06M
-99.11M
-100.70M
-65.04M
Income tax expense
-1.02M
-
-
-
Effective tax rate
0.93%
-
-
-
Other operating expenses
-
-
-
-
Net income
-108.04M
-99.11M
-100.70M
-65.04M
Net profit margin
-541.09%
-477.74%
-225.06%
-117.44%
Earnings per share
-1.85
-1.69
-1.69
-1.09
Interest and investment income
12.41M
10.80M
9.73M
8.88M
Interest expense
-
-
-
-
Net interest expenses
12.41M
10.80M
9.73M
8.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
-120.31M
-108.66M
-109.20M
-75.71M
Gain or loss from assets sale
-299.00K
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps